Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
Affected assets and topics
Why it matters
Tonix Pharmaceuticals has been approved to uplist from the Nasdaq Capital Market to the Nasdaq Global Select Market, indicating increased market credibility and potentially higher investor interest.
Article tone
Expected market reaction
Market impact analysis based on bullish sentiment with 90% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 52511
- Timeframe
- 6h
Prediction lifecycle
-
Llama 3.1 8B Instant (Groq) NASDAQ Bullish 90%Generated 6h Excluded
Expired: not evaluated within 7 days of its 6h timeframe elapsing
Logged at publication, scored automatically once the window closes — never edited.
Original source
BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market is expected to commence at the open of market on March 3, 2026, under the Company’s existing tic
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on March 3, 2026. Analysis and insights provided by AnalystMarkets AI.